Press Releases

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Press Releases

Jun 21, 2016
- Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS -  - Phase 3 Trial Expected to Commence in Q4 2016 - LONDON, June 21, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering,
May 31, 2016
LONDON, May 31, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin
May 05, 2016
- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome - - Initial LGS Phase 3 pivotal data expected in June - - Conference call today at 9:00 a.m. EDT , 2:00 p.m. BST - LONDON , May 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the
May 04, 2016
LONDON, May 04, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin
Apr 28, 2016
LONDON, April 28, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 May, 2016
Apr 21, 2016
LONDON, April 21, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S.
Mar 14, 2016
- Study in the treatment of Dravet syndrome — a rare and severe form of epilepsy in children with no FDA-approved treatments - - Primary endpoint achieved with high statistical significance (p=0.01) showing that Epidiolex treatment reduces convulsive seizures in children compared to placebo - -
Feb 10, 2016
-Three Phase 3 Epidiolex clinical trials fully recruited above target sample size — on track for initial data in March 2016- -Conference Call Today at 8:00 a.m. EST, 1:00 p.m. GMT- LONDON, Feb. 10, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the

Ways to keep up to date with GW